Was the recent market volatility just a fake out? After notching an all-time high on September 2, fears related to overheated valuations spurred …
Shares in Global Blood Therapeutics (GBT) rose 5% in Monday’s extended trading after the company announced plans to expand the potential use of …
Global Blood Therapeutics (GBT) has reported a solid first quarter earnings beat, with Q1 GAAP EPS of -$1.20 beating the Street forecast by $0.
At the end of the day, investors want to see returns. To accomplish this goal, seasoned Wall Street observers often turn to one …
Black Friday is past. So is Cyber Monday.
Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …
On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock …
Global Blood Therapeutics (NASDAQ:GBT) investors got cold feet today, sending shares tumbling nearly 17%. The reason?
One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.
Pain Therapeutics to try again with REMOXY NDA Investors love biotech stocks for the lottery ticket-like returns they can offer if a company …
